<DOC>
	<DOCNO>NCT02325960</DOCNO>
	<brief_summary>This 16-week , Single-center , Randomized , Open Label , Parallel Controlled Group Comparison Comprehensive Glycemic Control Exenatide Insulin Glargine Type 2 Diabetes Patients Inadequately Controlled With Metformin Monotherapy .</brief_summary>
	<brief_title>A Comparison Exenatide Insulin Glargine</brief_title>
	<detailed_description>Screening make select eligible patient , 44 patient receive stable dose metformin ( ≥1500 mg daily ) randomize ( 1:1 ) receive exenatide insulin glargine 16 week . Exenatide administer twice daily subcutaneous injection 30- 60 minute breakfast dinner ; dose 5 μg twice-daily first 4 week treatment 10 μg thereafter . Insulin glargine administer daily bedtime subcutaneous injection . The dose insulin glargine initiate ≥8 IU once-daily , titrate base dose algorithm target fast blood glucose ( FPG ) &lt; 6.1 mmol/L . Titration allow first 4 week . At end study , data collect analyzed .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Type2 diabetic patient stable , maximum tolerated dos metformin ( ≧1500mg/d , ≧8 week ) 3 . Male female age ≧ 18 year ≦70 year old 4 . HbA1c ≧7.0 ≦10 % 5 . BMI ≧ 24 kg/m2 1 . Known suspect allergy trial product relate product . 2 . Impaired renal function define serumcreatinine ≥ 1.5 mg/dl ( ≥ 133 umol/l ) . 3 . Acute chronic disease may cause tissue hypoxia respiratory failure shock . 4 . Abnormal liver function , alanine transaminase aspartate aminotransferase ≥ 3 fold normal upper limit , Total bilirubin ≥ 2 normal upper limit , acute alcohol intoxication , alcoholism . 5 . Subjects clinically significant , active ( past 12 month ) cardiovascular history ( include history myocardial infarction ( MI ) , arrhythmias conduction delay ECG , unstable angina , decompensated heart failure ( New York Heart Associationclass Ⅲ Ⅳ ) . 6 . Proliferative retinopathy muscular oedema require acute treatment . 7 . Pregnant positive pregnancy test screening , nurse mother , unwillingness use adequate contraception ( adequate contraceptive measure sterilization , intrauterine device , oral contraceptive barrier method ) . 8 . Treatment systemic corticosteroid within past two month prior screen . 9 . Type 1 diabetes mellitus . 10 . Receipt investigational drug within 1 month prior trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>exenatide</keyword>
	<keyword>insulin glargine</keyword>
</DOC>